Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator-Initiated, Multicenter, Phase II Clinical Trial of Allocetra (formerly referred to as off-the-shelf Allocetra) in COVID-19 Patients

Next Previous
Trial Profile

An Investigator-Initiated, Multicenter, Phase II Clinical Trial of Allocetra (formerly referred to as off-the-shelf Allocetra) in COVID-19 Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Oct 2020 According to an Enlivex Therapeutics media release, based on the positive results of the first five COVID-19 patients in this study, taken together with the results of Allocetra in 10 sepsis patients in a previous study, the company has determined to shift recruitment of additional patients from this investigator-initiated clinical trial into a larger Phase II clinical trial of COVID-19 patients in severe or critical condition as soon as reasonably practicable, subject to regulatory approval.
  • 01 Oct 2020 Results published in the Enlivex Therapeutics Media Release.
  • 10 Aug 2020 According to an Enlivex Therapeutics media release, the first patient has been dosed in this study with Allocetra in COVID-19 patients with severe illness and respiratory failures.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top